Carcinoma in situ of breast
Chapter 2:Neoplasms
ICD-10 D05 is a billable code used to indicate a diagnosis of carcinoma in situ of breast.
Carcinoma in situ of the breast refers to a non-invasive form of breast cancer where abnormal cells are found in the lining of the breast ducts or lobules but have not spread to surrounding breast tissue. This condition is often detected through mammography or breast biopsy and is classified into two main types: ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). DCIS is more common and is characterized by the presence of cancerous cells in the milk ducts, while LCIS is considered a marker for increased risk of developing breast cancer in the future. Patients diagnosed with carcinoma in situ typically have a favorable prognosis, but they require careful monitoring and management to prevent progression to invasive breast cancer. Treatment options may include surgery, radiation therapy, and hormone therapy, depending on the specific characteristics of the carcinoma and patient preferences. Surveillance protocols often involve regular mammograms and clinical breast exams to monitor for any changes that may indicate progression. The risk of progression to invasive cancer varies, with studies suggesting that approximately 30% of women with untreated DCIS may develop invasive breast cancer within 10 years.
Detailed pathology reports, treatment plans, and follow-up care documentation.
Diagnosis of DCIS or LCIS, treatment planning, and post-treatment surveillance.
Ensure accurate staging and grading of the carcinoma for proper coding.
Clear imaging reports and findings related to breast screenings.
Mammography findings leading to biopsy and diagnosis of carcinoma in situ.
Documenting the rationale for imaging and follow-up recommendations.
Used for surgical treatment of DCIS.
Operative report detailing the procedure and diagnosis.
Oncology specialists must ensure accurate coding based on the surgical approach.
DCIS is a non-invasive cancer that can progress to invasive cancer if untreated, while LCIS is not considered a cancer but indicates an increased risk of developing breast cancer in the future.
